Study reveals financial toll of duchenne MD on french families
NCT ID NCT06861270
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looked at the extra costs that families of people with Duchenne muscular dystrophy (DMD) in France have to pay out of their own pockets. It included 28 patients of any age who had been diagnosed for at least six months. The researchers measured things like uninsured medical treatments, home modifications, and lost income from caregiving, to get a full picture of the financial burden on families.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DUCHENNE MUSCULAR DYSTROPHY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
AP-HP Hôtel Dieu
Paris, 75004, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a lower steroid dose preserve strength in young boys with DMD?
- Can a targeted infusion slow muscle decline in duchenne? a new trial aims to find out.
- Can a massive patient database unlock new treatments for muscular dystrophy?
- Umbilical cord stem cells aim to slow muscle loss in duchenne boys
- Experimental drug aims to preserve arm and lung function in boys with advanced duchenne
- Experimental drug KER-065 aims to slow muscle decline in duchenne muscular dystrophy